Pfizer Outlicenses PARP Inhibitor To Clovis

Clovis Oncology will develop and commercialize a PARP inhibitor for solid tumors that was previously being developed by Pfizer.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet